The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: Implications for hepatitis C virus (HCV) therapy

Antiviral Research

Volumn 55, Issue 3, 2002, Pages 425-435

  Ouzounov, Serguey ^a,b   Mehta, Anand ^a,b   Dwek, Raymond A ^c   Block, Timothy M ^a,b   Jordan, Robert ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jefferson Ctr for Biomed Research   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bovine viral diarrhea virus (BVDV); Hepatitis C virus (HCV); Interferon 2b (IFN); n Butyl deoxynojirimycin (nB DNJ)

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; BUTYLDEOXYNOJIRIMYCIN; CASTANOSPERMINE; ENZYME INHIBITOR; GLUCOSIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BOVINE DIARRHEA VIRUS; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; HEPATITIS C; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE;

1-DEOXYNOJIRIMYCIN; ANIMALS; ANTIVIRAL AGENTS; CATTLE; DIARRHEA VIRUSES, BOVINE VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; PLAQUE ASSAY; REGRESSION ANALYSIS; TUMOR CELLS, CULTURED;

BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; HEPATITIS C VIRUS;

EID: 0036753024     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00075-X     Document Type: Article

References (34)

1. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 81:2000;1631-1648.
2. Bodenheimer H.C., Lindsay K.L., Davis G.L., Lewis J.H., Thung S.N., Seeff L.B. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: multicenter trial. Hepatology. 26:1997;473-477.
3. Brook M.G., McDonald J.A., Karayiannis P., Caruso L., Forster G., Harris J.R., Thomas H.C. Randomised controlled trial of interferon α-2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut. 30:1989;1116-1122.
4. Courageot M., Frenkel M., Dos Santos C.D., Deubel V., Despres P. α-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74:2000;564-572.
5. Davis G.L., Esteban-Mur R., Rustigo V., Hoeffs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M., Albrecht J. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl. J. Med. 339:1998;1493-1499.
6. Donis R.O. Molecular Biology of bovine viral diarrhea virus and its interactions with the host. Vet. Clin. North Am. Food Anim. Pract. 11:1995;393-423.
7. Durantel D., Branza-Nichita N., Carrouee-Durantel S., Butters T.D., Dwek R.A., Zitzmann N. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75:2001;8987-8998.
8. 3. J. Acquired Immune Defic. Syndr. 7:1994;139-147.
9. Fisher P.B., Karlsson G.B., Butters T., Dwek R., Platt F. N-Butyl-deoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J. Virol. 70:1996a;7143-7152.
10. Fisher P.B., Karlsson G.B., Dwek R., Platt F. N-butyl-deoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J. Virol. 70:1996b;7153-7160.
11. Gale M.J., Korth M.J., Tang N.M., Tan S.I., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., Katze M.G. Evidence that hepatitis C virus resistance to inteferon is mediated through repression of the PKR protein kinase by the nostructural 5a protein. Virology. 230:1997;217-227.
12. Gale M.J., Blakely C.M., Kwieciszewski B., Tan S., Dossett M., Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanism of kinase regulation. Mol. Cell. Biol. 18:1998;5208-5218.
13. Gillespie J.H., Robson D.S., Scott F.W., Schiff E.I. In vitro protective effect of bacteria-derived bovine α interferon 1 against selected bovine viruses. J. Clin. Microbiol. 22:1985;912-914.
14. Grakoui A., Hanson H.L., Rice C.M. Bad time for bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. Hepatology. 33:2001;489-495.
15. Heo D.S., Park J., Hata K., Day R., Herberman R.B., Whiteside T.L. Evaluation of tetrazolium based semiautomatic colorimetric assay for measurement of human ant-tumor cytotoxicity. Cancer Res. 50:1990;3681-3690.
16. Hulton M.R., Levin D.L., Freedman L.S. Randomized, placebo-controlled, double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J. Acquired Immune Defic. Syndr. 5:1992;1084-1090.
17. Johnson V.A., Barlow M.A., Merrill D.P., Chou T.C., Hirsch M.S. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-α A. J. Infect. Dis. 161:1990;1059-1067.
18. Kaufman R.J. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc. Natl. Acad. Sci. 96:1999;11693-11695.
19. Lane H.C., Davey V., Kovacs J.A., Feinberg J., Metcalf J.A., Herpin B., Walker R., Deyton L., Davey R.T., Falloon J. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112:1990;805-811.
20. Liang T.J. Combination therapy for hepatitis C infection. New Engl. J. Med. 339:1998;1549-1550.
21. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Inter. Med. 132:2000;296-305.
22. Mathews M.B. Translational Control. 1996;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
23. Mehta A., Carrouee S., Conyers B., Jordan R., Butters T., Dwek R.A., Block T.M. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology. 33:2001;1488-1495.
24. Pili R., Chang J., Partis R.A., Mueller R.A., Chrest F.J., Passaniti A. The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55:1995;2920-2926.
25. Poch G., Reiffenstein R.J., Unkelbach H.D. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. Can. J. Physiol. Pharmacol. 68:1990;682-688.
26. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interacts. Antiviral Res. 14:1990;181-206.
27. Reichard O., Norkrans G., Fryden A., Braconier J., Sonnerborg A., Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. The Lancet. 351:1998;83-87.
28. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:2001;778-809.
29. Schlesinger S., Koyama A.H., Malfer C., Gee S.L., Schlesinger M. The effects of inhibitors of glucosidase I o the formation of Sinbis virus. Virus Res. 2:1985;139-149.
30. Schlesinger S., Malfer C., Schlesinger M. The formation of vesicular stomatitis virus (San Juan Strain) becomes temperature-sensitive when glucose residues are retained on the oligosaccharides of the glycoproteins. J. Biol. Chem. 254:2000;7597-7601.
31. Senssui H., Takami R., Nishimori T., Murakami K., Yokoyama T., Yokomizo Y. Antiviral effect of interferon α on bovine viral diarrhea virus. J. Vet. Med. Sci. 60:1998;1329-1333.
32. Song J., Fujii M., Wang F., Itoh M., Hotta H. The NS5a protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J. Gen. Virol. 80:1999;879-886.
33. Taylor D., Shi S.T., Romano P.R., Barber G.N., Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 285:1999;107-110.
34. Zitzmann N., Mehta A., Carrouee S., Butters T., Platt F., McCauley J., Blumberg B., Dwek R., Block T.M. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. 96:1999;11878-11882.